Is Johnson & Johnson (JNJ) Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks

Simply Wall St.03-13 10:26

Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock recently closed at US$242.04, with returns ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619315400?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625","is_english":true,"pubTime":"2026-03-13 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619315400","market":"hk","top_or_hot":-1,"title":"Is Johnson & Johnson (JNJ) Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks","media":"Simply Wall St.","content":"<div>\n<p>Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock recently closed at US$242.04, with returns ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-johnson-johnson-jnj-pricing-reflect-its-strong-multiyear\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Johnson & Johnson (JNJ) Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Johnson & Johnson (JNJ) Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-johnson-johnson-jnj-pricing-reflect-its-strong-multiyear><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock recently closed at US$242.04, with returns ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-johnson-johnson-jnj-pricing-reflect-its-strong-multiyear\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640476718.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-johnson-johnson-jnj-pricing-reflect-its-strong-multiyear","article_id":"2619315400","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/is-johnson-johnson-jnj-pricing-reflect-its-strong-multiyear","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619315400","pubTimestamp":1773368774,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story?\nThe stock recently closed at US$242.04, with returns of 1.0% over the last week, 1.5% over the last month, 16.7% year to date, 52.6% over 1 year, 71.8% over 3 years and 73.7% over 5 years. These figures may influence how you think about its current value.\nRecent headlines around Johnson & Johnson have focused on its position as a major global...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999002232.USD":"Allianz Global High Payout USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","JNJ":"强生","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4568":"美国抗疫概念","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0882574055.USD":"富达全球健康医疗A ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","BK4532":"文艺复兴科技持仓","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC"},"translate_title":"强生公司(JNJ)的定价是否反映了其多年来的强劲上涨和法律总体风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"JNJ":1.5},"content_text":"Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock recently closed at US$242.04, with returns of 1.0% over the last week, 1.5% over the last month, 16.7% year to date, 52.6% over 1 year, 71.8% over 3 years and 73.7% over 5 years. These figures may influence how you think about its current value. Recent headlines around Johnson & Johnson have focused on its position as a major global healthcare company and ongoing attention around its product portfolio and legal exposures. These factors continue to influence how investors think about its risk profile and help frame why the recent share price performance may matter when you are weighing what the stock might be worth today. On our valuation checks, Johnson & Johnson scores 4 out of 6 for being undervalued, and you can see the full breakdown in the valuation score. Next, we will walk through the main valuation approaches investors tend to use, before finishing with a broader way of thinking about what this score really means.  Johnson & Johnson delivered 52.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. AdvertisementApproach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes future cash flow estimates, discounts them back to today using a required rate of return, and adds them up to arrive at an estimate of what the business might be worth right now. For Johnson & Johnson, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s latest twelve month free cash flow is about $19.7b. Analysts provide explicit free cash flow estimates out to 2030, with Simply Wall St extrapolating further projections beyond those analyst numbers within the same framework. On this basis, the DCF arrives at an estimated intrinsic value of about $382.80 per share. Compared with the recent share price of $242.04, this implies the stock screens as around 36.8% undervalued using this particular model and set of assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 36.8%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks. JNJ Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson. Approach 2: Johnson & Johnson Price vs Earnings For a profitable business like Johnson & Johnson, the P/E ratio is a useful way to think about value because it links what you pay for each share to the earnings that support that share today. What counts as a normal or fair P/E will usually reflect how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk tends to pull it down. Johnson & Johnson currently trades on a P/E of 21.8x. That sits above the Pharmaceuticals industry average of 18.0x, but below the peer group average of 23.7x. Simply Wall St also calculates a Fair Ratio, which is its view of what a more tailored P/E might be given factors such as Johnson & Johnson’s earnings growth profile, industry, profit margins, market cap and company specific risks. The Fair Ratio for Johnson & Johnson is 29.7x. Because this blends company fundamentals with its industry context, it can give a more rounded signal than a simple comparison with peer or industry averages. On this basis, the current 21.8x P/E is below the Fair Ratio of 29.7x, which indicates that the shares may screen as undervalued on this metric. Result: UNDERVALUED NYSE:JNJ P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are Simply Wall St community views that connect a clear story about Johnson & Johnson to specific forecasts for revenue, earnings and margins, then translate that into a Fair Value you can compare with today’s price to decide whether the stock looks attractive or not. In practice, a Narrative is your version of Johnson & Johnson’s future written into numbers. On Simply Wall St’s Community page you can see different investors doing exactly that. For example, one Narrative currently anchors on a Fair Value of about US$265.00 per share, while another sits closer to US$133.00. These reflect very different views on how the pharma pipeline, MedTech expansion and legal risks might play out over time. Because these Narratives are updated when new data, news or earnings are added to the platform, they give you a living framework rather than a static model. You can then decide which story and Fair Value range fits your own view of Johnson & Johnson, and how closely that lines up or diverges from the current share price of US$242.04. For Johnson & Johnson however we will make it really easy for you with previews of two leading Johnson & Johnson Narratives: 🐂 Johnson & Johnson Bull Case Fair Value: US$265.00 per share Implied pricing gap vs last close: around 8.7% below this fair value estimate Revenue growth assumption: 7.10% a year  Backs a broad group of 28 revenue platforms over US$1b each, across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, rather than relying on a single blockbuster. Leans on heavy R&D and M&A spend of over US$32b in 2025, with dozens of approvals, submissions and Phase III programs feeding a large late stage pipeline. Assumes Johnson & Johnson earns US$26.2b in 2029 at a 22.6% margin and trades on a P/E close to 29.9x. This would sit above the current US Pharmaceuticals industry multiple, while recognising concentration, pricing, cost, acquisition and legal risks.  🐻 Johnson & Johnson Bear Case Fair Value: US$173.55 per share Implied pricing gap vs last close: around 39.5% above this fair value estimate Revenue growth assumption: 6.30% a year  Highlights that the Kenvue spin off leaves Johnson & Johnson more focused on higher margin Pharmaceuticals and MedTech, but also more exposed to drug approvals, product uptake and key patent expiries. Assumes around 6% to 7.5% annual revenue growth to roughly US$120b by 2029 with a 20% profit margin, helped by a large late stage drug pipeline, MedTech acquisitions and cost optimisation. Values the stock using a 22x future P/E and a 5.8% discount rate, arriving at a present value of about US$174 per share. It also flags ongoing litigation, patent and pipeline execution risks as key swing factors.  If you want to see how other investors are joining the dots between Johnson & Johnson’s pipeline, legal exposures and cash generation, the full set of Narratives on Simply Wall St can give you a wider range of assumptions and fair value ranges to test against your own view. Curious how numbers become stories that shape markets? Explore Community Narratives Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying! NYSE:JNJ 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619315400","isCrawlerRequest":true}